Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Increased by Panagora Asset Management Inc.

Panagora Asset Management Inc. grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.7% in the 1st quarter, Holdings Channel reports. The firm owned 1,266,544 shares of the biopharmaceutical company’s stock after acquiring an additional 9,189 shares during the quarter. Panagora Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $79,957,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of BMY. Retirement Group LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $27,000. Orion Capital Management LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $28,000. Perennial Advisors LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth approximately $29,000. Brand Asset Management Group Inc. acquired a new stake in Bristol-Myers Squibb in the first quarter worth approximately $31,000. Finally, Alpha DNA Investment Management LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth approximately $33,000. 71.75% of the stock is owned by institutional investors.

Shares of NYSE:BMY opened at $67.10 on Friday. The company has a market capitalization of $149.82 billion, a PE ratio of -24.24, a PEG ratio of 1.25 and a beta of 0.64. Bristol-Myers Squibb has a 1 year low of $54.07 and a 1 year high of $67.96. The stock has a fifty day simple moving average of $64.84. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.56 and a quick ratio of 1.45.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Wednesday, April 28th. The biopharmaceutical company reported $1.74 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.82 by ($0.08). The business had revenue of $11.07 billion during the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a positive return on equity of 33.76% and a negative net margin of 14.53%. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.72 earnings per share. On average, equities analysts anticipate that Bristol-Myers Squibb will post 7.45 earnings per share for the current year.

In other Bristol-Myers Squibb news, SVP Joseph Eid sold 1,118 shares of the company’s stock in a transaction dated Monday, May 10th. The shares were sold at an average price of $65.00, for a total transaction of $72,670.00. Following the completion of the sale, the senior vice president now directly owns 8,069 shares in the company, valued at $524,485. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rupert Vessey sold 30,546 shares of the company’s stock in a transaction dated Wednesday, May 5th. The shares were sold at an average price of $64.29, for a total transaction of $1,963,802.34. Following the sale, the executive vice president now owns 45,139 shares of the company’s stock, valued at $2,901,986.31. The disclosure for this sale can be found here. Insiders have sold 74,783 shares of company stock valued at $4,770,493 over the last 90 days. Corporate insiders own 0.11% of the company’s stock.

BMY has been the subject of a number of research analyst reports. Truist upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, April 13th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $62.00 price target on shares of Bristol-Myers Squibb in a report on Thursday, May 6th. Truist Financial raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, April 13th. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a report on Tuesday, April 6th. Finally, TheStreet raised shares of Bristol-Myers Squibb from a “c” rating to a “b” rating in a research note on Thursday, April 29th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $72.36.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Featured Story: What is the Gross Domestic Product (GDP)?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.